Abstract
Initially developed as glucose-lowering agents for the treatment of type 2 diabetes, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of important clinical endpoints, such as hospitalization for heart failure (HHF), death from cardiovascular (CV) causes, anddeath from any causes among patients with chronic heart failure or chronic kidney disease, regardless of the presence or absence ofdiabetes [...]. In this study, we aimed to determine whether the composite of HHF or CV death can serve as a valid surrogate endpoint for death from any cause [...].